JP2010526858A - 甲状腺ホルモンを含んでなる新たな医薬組成物及びその治療的使用 - Google Patents

甲状腺ホルモンを含んでなる新たな医薬組成物及びその治療的使用 Download PDF

Info

Publication number
JP2010526858A
JP2010526858A JP2010507939A JP2010507939A JP2010526858A JP 2010526858 A JP2010526858 A JP 2010526858A JP 2010507939 A JP2010507939 A JP 2010507939A JP 2010507939 A JP2010507939 A JP 2010507939A JP 2010526858 A JP2010526858 A JP 2010526858A
Authority
JP
Japan
Prior art keywords
rats treated
rats
results
treated
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010507939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526858A5 (enExample
Inventor
レベーブ，ザビエル
タロー，ネリー
ファビエール，ローラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of JP2010526858A publication Critical patent/JP2010526858A/ja
Publication of JP2010526858A5 publication Critical patent/JP2010526858A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010507939A 2007-05-16 2008-05-16 甲状腺ホルモンを含んでなる新たな医薬組成物及びその治療的使用 Withdrawn JP2010526858A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290635A EP1992341A1 (en) 2007-05-16 2007-05-16 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
PCT/EP2008/056076 WO2008138995A1 (en) 2007-05-16 2008-05-16 New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2010526858A true JP2010526858A (ja) 2010-08-05
JP2010526858A5 JP2010526858A5 (enExample) 2011-05-12

Family

ID=38562932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010507939A Withdrawn JP2010526858A (ja) 2007-05-16 2008-05-16 甲状腺ホルモンを含んでなる新たな医薬組成物及びその治療的使用

Country Status (7)

Country Link
US (1) US20110064773A1 (enExample)
EP (2) EP1992341A1 (enExample)
JP (1) JP2010526858A (enExample)
CN (1) CN103282031A (enExample)
BR (1) BRPI0811636A2 (enExample)
CA (1) CA2687385A1 (enExample)
WO (1) WO2008138995A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526502A (ja) * 2020-05-21 2023-06-21 イクイリブレイト セラピューティクス， エルエルシー 甲状腺ホルモンレベルを制御するためのマイクロニードルデバイス

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
WO2013006402A1 (en) * 2011-07-01 2013-01-10 Thomas Najarian Methods and compositions for facilitating weight loss by administration of thyroid hormones
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
CN108037276A (zh) * 2017-11-28 2018-05-15 泰州泽成生物技术有限公司 磁微粒化学发光法测定rT3含量的试剂盒及其检测方法
CN116270581A (zh) * 2023-02-28 2023-06-23 山东大学 碘塞罗宁在制备治疗动脉粥样硬化药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
EP2068858A1 (en) * 2007-05-16 2009-06-17 Université Joseph Fourier New pharmaceutical compositions comprising diiodothyronine and their therapeutic use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526502A (ja) * 2020-05-21 2023-06-21 イクイリブレイト セラピューティクス， エルエルシー 甲状腺ホルモンレベルを制御するためのマイクロニードルデバイス
JP7840272B2 (ja) 2020-05-21 2026-04-03 イクイリブレイト セラピューティクス， エルエルシー 甲状腺ホルモンレベルを制御するためのマイクロニードルデバイス

Also Published As

Publication number Publication date
WO2008138995A1 (en) 2008-11-20
CN103282031A (zh) 2013-09-04
BRPI0811636A2 (pt) 2014-11-11
US20110064773A1 (en) 2011-03-17
EP2068859A1 (en) 2009-06-17
EP1992341A1 (en) 2008-11-19
CA2687385A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
US5834032A (en) Compositions and methods for treating diabetes
Owen et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
RU2498795C2 (ru) Способы лечения неалкогольного стеатогепатита (nash) с применением цистеаминовых продуктов
Beard Feed efficiency and norepinephrine turnover in iron deficiency
FR3125409A1 (fr) Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine
Watała et al. Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats
US20110064773A1 (en) pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
US20100069498A1 (en) Use of alpha-ketoglutaric acid for the treatment of high plasma glucose condition
CZ265199A3 (cs) Použití inhibitorů gastrointestinální lipasy
Larner D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work.
WO2005009433A1 (en) Use of 3,5 diiodothyronine as regulators of lipid metabolism
JP2010526857A (ja) ジヨードチロニンを含んでなる新規な医薬組成物及びその治療的使用
JP2015536330A (ja) トリメチルアミン−ｎ−オキシドのレベルを下げる医薬組成物
JPWO2003068215A1 (ja) ミトコンドリア病用薬剤
Stacpoole Pangamic acid (vitamin B15)
Weissman et al. Starvation
ES2972498T3 (es) Composición y método para la prevención y tratamiento de la diabetes tipo 2
ES2972490T3 (es) Composición y método para el tratamiento de la diabetes de tipo I
Palled Pharmacokinetic and antidiabetic activity of newly developed oral insulin delivery system
Ali A new approach in type 2 diabetes mellitus treatment: Evaluation of the beneficial effect of L-cysteine in the treatment of type 2 diabetes mellitus
JP2004525141A (ja) 抗糖尿病ならびに低脂血症薬としてのエストロゲン脂肪酸モノエステル
US20080188439A1 (en) Directed metabolism of compounds by glucuronidation and sulfonation donors to decrease toxicity
CN116940361A (zh) 美托哌丙嗪及其盐的代谢方法
CN101478974A (zh) 用于诱导受试对象休眠的方法及组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110323

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121002